Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Newly Independent Myriad Diagnostics Will Pursue Product Acquisitions

This article was originally published in The Pink Sheet Daily

Executive Summary

Pharmaceutical group to proceed as an independent developer of cancer, infectious disease therapies.
Advertisement

Related Content

ACOG Guideline Revisions Boost Myriad’s BRCA Test
ACOG Guideline Revisions Boost Myriad’s BRCA Test
Strong Abraxane Cancer Data Promised, But Abraxis Mum On Spin-Off Details
Strong Abraxane Cancer Data Promised, But Abraxis Mum On Spin-Off Details
Myriad Gets Phase IIb HIV Maturation Inhibitor From Panacos For $7M
Myriad Gets Phase IIb HIV Maturation Inhibitor From Panacos For $7M
Gilead, Myriad Top J.P. Morgan’s 2009 Short List
Gilead, Myriad Top J.P. Morgan’s 2009 Short List
Myriad Weighs Strategic Alternatives
Myriad Weighs Strategic Alternatives

Topics

Advertisement
UsernamePublicRestriction

Register

PS066919

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel